MaxCyte, Inc. Trading Update (6024J)
December 23 2020 - 2:00AM
UK Regulatory
TIDMMXCT TIDMTTM
RNS Number : 6024J
MaxCyte, Inc.
23 December 2020
TRADING UPDATE
MaxCyte to exceed 2020 Full Year market expectations
Gaithersburg, Maryland - 23 December 2020: MaxCyte (LSE: MXCT,
MXCL), a global cell-based therapies and life sciences company,
today announces an update on trading for the full year 2020 and
progress of the CARMA programme.
Based on ongoing momentum in transformational cell therapies and
milestone payments from growth in clinical and commercial license
partnerships, MaxCyte expects financial results to be ahead of
market expectations for the full-year in the core life sciences
business (before CARMA costs). A more detailed trading update will
be announced the week of 18 January 2021 .
MaxCyte continues to work with Locust Walk on the strategy and
future funding of the Group's CARMA business, and enrolment and
dosing in the existing CARMA no-preconditioning MCY-M11 clinical
study is continuing well. The Company will provide a further update
in January.
MaxCyte President & CEO, Doug Doerfler, said: "We have seen
sustained strong growth in our core life sciences business as
demand for our next generation gene and cell therapy enabling
products continues to expand internationally, despite the issues
that COVID-19 has placed around the globe. MaxCyte continues to be
uniquely positioned to capitalise on the rapidly growing cell
therapy market."
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company. As the inventors of the premier cell-engineering
enabling technology, the Company helps bring the promise of
next-generation cell and gene-editing therapies to life. The
Company's technology is currently being deployed by leading drug
developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte licences have been granted for
more than 120 cell therapy programmes, with more than 90 licensed
for clinical use, and the Company has now entered into eleven
clinical/commercial license partnerships with leading cell therapy
and gene editing developers. MaxCyte was founded in 1998, is listed
on the London Stock Exchange (LSE: MXCT, MXCL) and is headquartered
in Gaithersburg, Maryland, US. For more information, visit
www.maxcyte.com .
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) No 596/2014 (MAR).
Contacts:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Amanda Murphy, Chief Financial
Officer +1 301-944-1660
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden +44 (0)20 7886 2500
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith +44 (0)20 7260 1000
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott
Chris Welsh
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TSTZZMZZZZFGGZZ
(END) Dow Jones Newswires
December 23, 2020 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024